Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients With Selected Solid Tumors

NCT02451007 is registered in ClinicalTrials.gov with PharmaMar as lead sponsor.

NCT NCT02451007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02451007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients With Selected Solid Tumors
Lead sponsor
PharmaMar
Phase
Phase 2
Overall status
Completed
Start date
August 12, 2015
Completion date
August 19, 2016
Enrollment
39 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors